Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019163 (hepatitis B)
 38,309 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

As part of a 10-year health sector reform effort, the government of Bolivia is collaborating with the Pan American Health Organization and the World Bank to increase coverage of vaccines included in the national immunization program and to introduce other important vaccines (such as yellow fever vaccine in affected areas and vaccination against hepatitis B in endemic areas) into the program. Financing will be covered by a World Bank loan of US $6.5 million, grants from international agencies ($4.5 million), and $9 million from the government. A 5-year plan offers specific strategies to 1) strengthen the national immunization program to improve adoption and implementation of immunization policies, 2) strengthen health services to improve coverage and introduce other vaccines, and 3) strengthen the information and surveillance systems. Indicators to monitor implementation of the project will include 1) coverage of DPT3 dose in 1999 and coverage with pentavalent 3 vaccine by the year 2000; 2) the number of municipalities with DPT3 coverage less than 80% and the number with pentavalent 3 coverage less than 80% by 2000; and 3) national financing of immunization programs.
EPI Newsl 1999 Apr
PMID:Bolivia benefits from PAHO / World Bank partnership. 1234 86

Ecuador conducted its National Immunization Day on August 2-13, 1999, against 10 vaccine-preventable diseases, and distributed vitamin A supplementation to children between the ages of 6 to 36 months. The goals of the campaign were: 1) indiscriminate vaccination with oral polio vaccine of all children under 5 years old; 2) nationwide introduction of measles, mumps, and rubella vaccines to all children aged 12-23 months; 3) hepatitis B vaccine introduction to all children below 1 year in the eastern part of the country, vaccination with dT of 60% of all women of childbearing age in 71 areas identified at risk for neonatal tetanus, and nationwide vaccination with dT of all pregnant women; and 4) yellow fever immunization of all children aged 1-14 years in the eastern provinces located in the Amazon Basin and of all adults aged 15-49 years in the provinces of Sucumbios, Napo, Orellana, and the area of Mumullacta in Pastanza.
EPI Newsl 1999 Aug
PMID:Ecuador holds National Immunization Day. 1234 62

Combination vaccines have been introduced in Mexico. The national immunization program has incorporated the measles-mumps-rubella (MMR) vaccines in 1998, and the pentavalent vaccine in 1999. The two categories of antigen composition in combination vaccines are: 1) multiple different antigenic types of a single pathogen, such as the 23 valent pneumococcal polysaccharide vaccine, and 2) antigens from different pathogens causing different diseases, such as the DPT and MMR vaccines. Pentavalent vaccines are included in the second category. The vaccine protects against diphtheria, tetanus, pertussis, hepatitis B, and other diseases produced by Haemophilus influenzae type b (Hib). Combined diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenza type b (DTP-HB/Hib) vaccine has been distributed to 87% of Mexican children under 1 year of age. Over 800,000 doses of pentavalent vaccine have been administered.
EPI Newsl 1999 Aug
PMID:Mexico introduces pentavalent vaccine. 1234 63

Hepatocellular carcinoma (HCC) etiology and incidence in Madagascar are not well established. The work presented here is the first documented study on HCC in Madagascar. The study was undertaken at the Centre Hospitalier de Soavinandriana, Antananarivo, from October 1995 to October 1996. Hepatocellular carcinoma was reported in 19 out of 22 patients with liver tumor included in the study. In 6 cases, patients developed post alcoholic cirrhosis HCC. Hepatitis B virus markers were detected in 48% of cases (13/19). The HBs Ag was detected in 42% of cases (8/19) in association with HBe Ag in 16% of cases (3/19), and hepatitis C virus antibodies in 11% of cases (2/18). In 3 cases, the etiology remained unknown. Hepatocellular carcinoma appeared the most frequent liver cancer, mainly due to post-hepatitis B cirrhosis. The introduction of hepatitis B vaccine in EPI (Expanded Program of Immunization) is recommended in order to reduce the percentage of hepatitis B virus carriers in the malagasy population and furthermore the incidence of HCC.
 ...
PMID:[Etiology of hepatocellular carcinomas in Madagascar: results of a study in Antananarivo from October 1995 to October 1996]. 1246 21

Hib vaccine is the 8th vaccine knocking at the door to be included in the EPI the world over. However there are some controversies that need to be addressed, especially when it comes to use of this vaccine in India. It is difficult to culture Hib unless one uses sheep blood enriched media for culture. There is a lack of good community based data on Hib burden in India. This makes many feel that Hib is rare in India. However this is not true. There are many studies that have looked at this closely. Hib is a common cause of meningitis and pneumonitis in children less than 5 years old in India. There is wide spread problem of multi-drug resistance by Hib in India. Mortality of meningitis is as high as 100% if third generation cephalosporins are not used in time. Of the survivors of meningitis, 60% develop long-term sequelae. Hib vaccine is very effective and can lead to 99% reduction with mass vaccination in just 2-3 years. It is also a very safe vaccine. Of the conjugated vaccines available in India all are equally effective and safe and there is nothing to choose one over the other. There is a need to give a booster dose at 15-18 months of age. Even UK, which never gave the booster dose, is seriously thinking of changing their practice and give a booster dose. Lastly the combination vaccines of Hib with IPV, DPwT/DPaT, and Hepatitis B are safe and effective and should be encouraged to improve the compliance. The use of Hib vaccine is recommended in India, for those who can afford the vaccine.
 ...
PMID:H. influenzae type b (Hib) vaccine--controversies. 1292 18

Hepatitis B virus (HBV) infection is one of the most prevalent public health problems worldwide, and causes 1 million deaths annually. In Bangladesh, information about prevalence of HBV infection is scarce, and there is no available data on HDV infection. We determined rates of HBsAg and anti-HBc seropositivity in asymptomatic, healthy children (n = 181) and adults (n = 354) presenting to referral facilities in Dhaka, Bangladesh, and tested a separate group of HBsAg-positive patients (n = 180) for prevalence of HDV. Testing of serum was also performed for signs of liver disease. Overall, seropositivity of HBsAg and anti-HBc in studied subjects was 3 per cent (16/534) and 21.1 per cent (113/534), respectively. Prevalence of HBsAg was highest in the 5- to 9-year-old (8.5 per cent, 7/82) and 10- to 14-year-old (5.9 per cent, 2/34) age groups. Unlike HBsAg, prevalence of anti-HBc was lower in children (14.9 per cent in those below the age of 15) than adults (24.4 per cent in those aged 20-34 years) (p < 0.05). Most HBsAg-positive individuals were symptomatic (n = 125, 69.4 per cent). A high rate (24.4 per cent, 44/180) of simultaneous infection with HDV was observed among HBsAg-positive subjects, with higher rates in older individuals. Anti-HDV seropositivity rate was similar among asymptomatic (21.8 per cent, 12/55) and symptomatic (25.6 per cent, 32/125) HBsAg carriers. Our data suggest that Bangladesh is of moderate endemicity for HBV infection, and has relatively high rates of co-infection with HDV. Control HBV and HDV infection in Bangladesh may be best achieved by targeting preschool children, which could fit readily within the existing EPI schedule.
 ...
PMID:Seroepidemiology of hepatitis B and delta virus infections in Bangladesh. 1472 15

Host genetic factors and environment factors including hepatitis B virus (HBV) genotypes are widely studied for the different outcomes of HBV infection. Recent studies suggest that tumour necrosis factor-alpha (TNF-alpha) plays a pivotal role in the viral clearance and host immune response to HBV, and the capacity for TNF-alpha production in individuals is influenced by a major genetic component. In this study, we aimed to explore whether the single-nucleotide polymorphisms (SNPs) of TNF-alpha promoter are associated with the outcomes of HBV infection in the Chinese Han population. One hundred and forty-three spontaneously recovered HBV subjects and 196 chronic hepatitis B patients were recruited in this case-control study in the Beijing area of China. Polymerase chain reaction-restriction fragment-length polymorphism (PCR-RFLP) and sequence-specific primer-PCR (SSP-PCR) were used to detect the SNPs of five sites in the TNF-alpha promoter (-238G/A, -308G/A, -857C/T, -863C/A, -1031T/C). The frequency distributions of genotypes and haplotypes in two groups were analysed by EPI and EH programs. The presence of the -238GG genotype was significantly correlated with persistence of HBV infection (OR = 4.08, P = 0.02), and -857TT genotype appeared in relation to the spontaneous clearance of HBV (OR = 0.47, P = 0.03). Frequency of haplotype GGCCT (-238/-308/-857/-863/-1031) in the chronic HB group was significantly lower than that in spontaneously recovered group (P = 0.03), and frequencies of haplotypes GGCAT and GGTAT in the chronic HB group were significantly higher than those in the spontaneously recovered group (P = 0.0001, P = 0.0004). In conclusion, TNF-alpha promoter polymorphisms are independently associated with different outcomes of HBV infection.
 ...
PMID:Association of TNF-alpha promoter polymorphisms with the outcomes of hepatitis B virus infection in Chinese Han population. 1690 49

New combination vaccines and reliable sources of vaccine components are essential to ensure the success of mass immunisation programmes in the 21st century. We evaluated a new combined diphtheria-tetanus-whole-cell-pertussis-hepatitis B vaccine, extemporaneously mixed with a Haemophilus influenzae type b conjugate vaccine (DTPw-HBV/Hib) containing 2.5 microg PRP in 913 Philippino infants, administered according to the EPI schedule at 6, 10 and 14 weeks of age after a birth dose of hepatitis B vaccine (HBV; trial DTPw-HBV/Hib-001). One month after the third dose of DTPw-HBV/Hib (N = 182), 99.4% and 94.2% of subjects had anti-PRP antibody levels > or =0.15 microg/mL and > or =1.0 microg/mL, respectively. In addition, 95.9%, 100.0% and 87.6% of subjects had seroprotective antibody concentrations against diphtheria, tetanus and hepatitis B, respectively. The seroprotection rate to hepatitis B increased significantly to 94.3% in subjects who received a dose of HBV at birth. The pertussis vaccine response rate was > or =95%. Seroprotection/vaccine response rates to all antigens after DTPw-HBV/Hib were at least as good as those observed after vaccination with GSK Biologicals' licensed Tritanrix HepB/Hiberix (containing 10 microg PRP) which was used as comparator. Although redness >20 mm in diameter and fever > or = 37.5 degrees C (axillary route) occurred more often after the new DTPw-HBV/Hib vaccine (p < 0.05), other Grade 3 adverse events occurred similarly between the groups. The new DTPw-HBV/Hib vaccine was as immunogenic and well tolerated as the licensed control vaccine when administered according to the immunologically challenging EPI schedule. A birth dose of HBV is important to maximize protection against hepatitis B in endemic regions where the EPI schedule is in place.
 ...
PMID:A new DTPw-HBV/Hib vaccine is immunogenic and safe when administered according to the EPI (Expanded Programme for Immunization) schedule and following hepatitis B vaccination at birth. 1701 60

To assess changes in infant vaccination coverage in Flanders since 1999, an EPI-survey was performed in 2005. The parents of 1354 children aged 18-24 months were interviewed at home and the vaccination documents were checked. Several factors possibly related to vaccination status were examined with parametric and non-parametric methods. The coverage rate of recommended vaccines, i.e. poliomyelitis, tetanus-diphtheria-pertussis, H. influenzae type b (Hib), hepatitis B, measles-mumps-rubella (MMR) and meningococcal C, reached at least 92.2%, which is a significant rise for MMR, hepatitis B and Hib since 1999. The vaccinating physician, the employment situation of the mother and the family income were significant predictive factors for having received all recommended vaccine doses (complete schedule), also when considering only doses that were according to minimal age and interval criteria (valid schedule).
 ...
PMID:Infant vaccination coverage in 2005 and predictive factors for complete or valid vaccination in Flanders, Belgium: an EPI-survey. 1752 28

The Expanded Programme on Immunisation provides an opportunity to deliver vitamin A supplements to young infants in order to improve their vitamin A status. However, concerns have been raised about the safety of administering high dose vitamin A supplements to infants less than 6 months of age in developing countries. A randomized controlled trial was carried out by the Kintampo Health Research Centre to assess the safety and immunogenicity of administering 15 mg retinol equivalent (RE)1 vitamin A alongside the pentavalent "diphtheria-polio-tetanus-Haemophilus influenzae b-hepatitis B vaccine" at 6, 10 and 14 weeks of age. All mothers received a post-partum supplement of 120 mg RE vitamin A as per national policy. Mothers of infants who had been vaccinated were visited 24 h after vaccination to assess the side effects of the vaccine. They were also interviewed about adverse events which may have occurred in the past 4 weeks since the child was vaccinated. There were significantly fewer reports of illnesses and fever in infants who had been given vitamin A compared to infants in the control group. The pentavalent vaccine was found to be tolerable when administered with vitamin A according to the WHO/EPI schedule for infant immunisation at 6, 10 and 14 weeks. There were few complaints made by the mothers of the children which were not thought to be related to giving vitamin A with the vaccines. There were six deaths in the trial, five in the intervention group and one in the control RR 4.65 (0.55-39.5), p = 0.12. Due to the high point estimate of 4.65, we wish to urge caution in administering high doses of vitamin A to young infants with the pentavalent vaccine at 6, 10 and 14 weeks of age.
 ...
PMID:Vitamin A supplements are well tolerated with the pentavalent vaccine. 1883 14


<< Previous 1 2 3 4 5 Next >>